Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention.
OBJECTIVE
To assess the cost implications for a preventive treatment strategy for institutionalised elderly women with a combined 1200 mg/day calcium and 800 IU/day vitamin D(3) supplementation in seven European countries.


METHODS
Retrospective cost effectiveness analysis based on a prospective placebo-controlled randomised clinical trial.


METHODS
Recently published cost studies in seven European countries. Clinical results from Decalyos, a 3-year placebo-controlled study in elderly institutionalised women.


METHODS
Decalyos study, with 36 months follow-up of 3270 mobile elderly women living in 180 nursing homes, allocated to two groups. One group received 1200 mg/day elemental calcium in the form of tricalcium phosphate together with 800 IU/day (20 microg) of cholecalciferol (vitamin D(3)), the other placebo.


RESULTS
In the 36 months analysis of the Decalyos study, 138 hip fractures occurred in the group of 1176 women, receiving supplementation and 184 hip fractures in the placebo group of 1127 women. The mean duration of treatment was 625.4 days. Adjusted to 1000 women, 46 hip fractures were avoided by the calcium and vitamin D(3) supplementation. For all countries, the total costs in the placebo group were higher than in the group receiving supplementation, resulting in a net benefit of 79000-711000 per 1000 women.


CONCLUSIONS
This analysis suggests that the supplementation strategy is cost saving. The results may underestimate the net benefits, as this treatment has also shown to be effective in decreasing the incidence of other non-vertebral fractures in elderly institutionalised women.
Lilliu
Hervé
H
CLP-Santé, 9-11 rue du Mont Aigoual, F-75015 Paris, France. herve.lilliu@clp-sante.fr
Pamphile
Raymond
R
Chapuy
Marie Claire
MC
Schulten
Jeltje
J
Arlot
Monique
M
Meunier
Pierre J
PJ
D000368:Aged; D002130:Calcium Phosphates / Q000008:administration & dosage* / Q000191:economics; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D017048:Health Care Costs; D006620:Hip Fractures / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000191:economics
D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D002762:Cholecalciferol; C018392:tricalcium phosphate